Reduction in work and activity impairment within 6 months of benralizumab initiation in Canadians with severe eosinophilic asthma
E. Penz (Saskatoon, Canada), S. Kayaniyil (Mississauga, Canada), B. Lancaster (Mississauga, Canada), B. Francoeur (Trois-Rivières, Canada), J. Lee (Toronto, Canada), M. Mallet (Bathurst, Canada), O. Tourin (Calgary, Canada), W. Ramesh (Edmonton, Canada), M. Mahdavian (Barrie, Canada), B. Walker (Calgary, Canada), Z. Belak (Regina, Canada), A. Thawer (Calgary, Canada), V. Dhawan (Edmonton, Canada), L. Mbuagbaw (Hamilton, Canada), S. Noorduyn (Mississauga, Canada)
Source: International Congress 2022 – Studies targeting IL-5 pathways in asthma
Session: Studies targeting IL-5 pathways in asthma
Session type: Thematic Poster
Number: 2123
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Penz (Saskatoon, Canada), S. Kayaniyil (Mississauga, Canada), B. Lancaster (Mississauga, Canada), B. Francoeur (Trois-Rivières, Canada), J. Lee (Toronto, Canada), M. Mallet (Bathurst, Canada), O. Tourin (Calgary, Canada), W. Ramesh (Edmonton, Canada), M. Mahdavian (Barrie, Canada), B. Walker (Calgary, Canada), Z. Belak (Regina, Canada), A. Thawer (Calgary, Canada), V. Dhawan (Edmonton, Canada), L. Mbuagbaw (Hamilton, Canada), S. Noorduyn (Mississauga, Canada). Reduction in work and activity impairment within 6 months of benralizumab initiation in Canadians with severe eosinophilic asthma. 2123
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|